TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35393218
Drug: Full 90-minute
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full 90-minute HBOT dose
Study: 33891380
Drug: Bimekizumab (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimekizumab (320 mg subcutaneously every 4 weeks)
Study: 33891380
Drug: Secukinumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab (300 mg subcutaneously weekly to week 4, then every 4 weeks)
Study: 34172470
Drug: Continuing mepolizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuing mepolizumab 100 mg every 4 weeks
Study: 34247980
Drug: Conventional fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional fluid therapy (Control)
Study: 34909045
Drug: L-carnitine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (1.5 g daily for six days)
Study: 33765054
Drug: Adenosine (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine (18 mg intravenous bolus)
Study: 34166000
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (n = 203)
Study: 35361691
Drug: Two-dose vaccination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-dose vaccination
Study: 33010241
Drug: Dolutegravir 50
Normalized name: dolutegravir 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir 50 mg
Study: 35430238
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ulipristal acetate daily
Study: 35430238
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg ulipristal acetate daily
Study: 35430238
Drug: Cyclic regimen
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic regimen of 5 mg ulipristal acetate for 24 days followed by four placebo days
Study: 35430238
Drug: All ulipristal
Approvals — FDA: no, EMA: no, PMDA: no
Description: All ulipristal acetate treatments
Study: 35430238
Drug: Endometrial biopsies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endometrial biopsies during treatment
Study: 35430238
Drug: Cyclic regimen
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic regimen of 5 mg ulipristal acetate
Study: 34792161
Drug: Higher dialysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dialysate sodium concentration (142 mmol/L)
Study: 34792161
Drug: Lower dialysate
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dialysate sodium concentration (138 mmol/L)
Study: 32562632
Drug: Late-parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late-parenteral nutrition
Study: 32562632
Drug: Early-parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early-parenteral nutrition
Study: 35112386
Drug: Essential Health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential Health Care Programme (EHCP) - daily toothbrushing with fluoride toothpaste
Study: 35112386
Drug: EHCP +
Approvals — FDA: no, EMA: no, PMDA: no
Description: EHCP + Fluoride - weekly application of high-concentrated fluoride gel
Study: 35112386
Drug: EHCP +
Approvals — FDA: no, EMA: no, PMDA: no
Description: EHCP + OUT - twice-yearly access to on-demand urgent oral treatment
Study: 35112386
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group - standard school-based oral health education
Study: 32073559
Drug: Gastroftal eye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastroftal eye drops and tablets (Group B)
Study: 36481516
Drug: 3P intervention
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3P intervention (combination of imaginal retraining and decoupling)
Study: 34479958
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human parathyroid hormone (1-84)
Study: 36090002
Drug: Jintiange capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jintiange capsules (1.2 g each time, 3 times per day) and alfacalcidol (0.25 μg/d)
Study: 36090002
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (element calcium 0.3 g, twice a day) and alfacalcidol (0.25 μg/d)
Study: 35010445
Drug: e-mail-delivered cognitive
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: e-mail-delivered cognitive behavioral therapy for insomnia (CBT-I) (REFRESH)
Study: 34894470
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg terazosin (TZ)
Study: 34883313
Drug: Disease-modifying treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disease-modifying treatment available
Study: 36456480
Drug: Ergometrine combined
Normalized name: Ergometrine
DrugBank: Ergometrine (DB01253)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ergometrine combined with oxytocin (intra-myometrial injection following oxytocin intravenously)
Study: 36456480
Drug: Oxytocin alone
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin alone (intra-myometrial injection following oxytocin intravenously)
Study: 36420866
Drug: Honey (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Honey (1 g kg-1 day-1) and Nigella sativa seeds (80 mg kg-1 day-1)
Study: 32481277
Drug: Shexiang Tongxin
Normalized name: CAMPHOR (NATURAL) 30.53 mg / MENTHOL 40.71 mg / METHYL SALICYLATE 25.95 mg TOPICAL PLASTER [SheXiang ZhuangGu Gao]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shexiang Tongxin Dropping Pills (STDP) combined with routine medicine
Study: 32481277
Drug: Nicorandil combined
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil combined with routine medicine
Study: 32481277
Drug: STDP combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: STDP combined with routine medicine
Study: 33090380
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for 12 months
Study: 32049331
Drug: Iron isomaltoside
Normalized name: Iron isomaltoside 1000
DrugBank: Iron isomaltoside 1000 (DB12208)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron isomaltoside 1000/ferric derisomaltose (IIM) - single dose of 1000 mg IV
Study: 32049331
Drug: Iron sucrose
Normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron sucrose (IS) - administered as 200 mg IV injections up to five times within a 2-week period
Study: 34923901
Drug: Oral fecal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fecal microbiota transplantation (FMT) capsules for 12 weeks (A3)
Study: 34923901
Drug: Oral empty
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral empty capsules for 12 weeks (B3)
Study: 35356935
Drug: Acupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture plus antihypertensive drugs
Study: 32045259
Drug: Antihypertensive drugs
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive drugs only (Control)
Study: 35714267
Drug: Crossover to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossover to active treatment from sham-control
Study: 33203003
Drug: Isoflavone supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone supplementation (100 mg/day) and exercise
Study: 35815739
Drug: omega-3 PUFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: omega-3 PUFA supplementation (1020 mg daily for 12 weeks)
Study: 33513026
Drug: Elacestrant 400
Normalized name: Elacestrant
DrugBank: Elacestrant (DB06374)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elacestrant 400 mg orally once daily
Study: 35584336
Drug: Standard-of-care (SOC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care (SOC) endocrine monotherapy
Study: 36401521
Drug: Lanolin treatment
Normalized name: Lanolin
DrugBank: Lanolin (DB11112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanolin treatment
Study: 36401521
Drug: Human milk
Normalized name: HUMAN MILK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human milk treatment
Study: 35367282
Drug: Seladelpar 2
Normalized name: Seladelpar
DrugBank: Seladelpar (DB12390)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seladelpar 2 mg/day
Study: 35367282
Drug: Seladelpar 5
Normalized name: Seladelpar
DrugBank: Seladelpar (DB12390)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seladelpar 5 mg/day
Study: 35367282
Drug: Seladelpar 10
Normalized name: seladelpar 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seladelpar 10 mg/day
Study: 35367282
Drug: Seladelpar 5
Normalized name: Seladelpar
DrugBank: Seladelpar (DB12390)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seladelpar 5 mg/day and 10 mg/day
Study: 32183815
Drug: Park Prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Park Prescription Intervention (PPI): Face-to-face Park Prescription + invitation to weekly exercise sessions in parks
Study: 34046921
Drug: STR-324 (0.004-11.475
Approvals — FDA: no, EMA: no, PMDA: no
Description: STR-324 (0.004-11.475 mg h-1)
Study: 34046921
Drug: STR-324 (1.25-11.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: STR-324 (1.25-11.25 mg h-1)
Study: 36218094
Drug: Sublingual administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual administration of carboprost combined with oxytocin (20IU oxytocin and small pot drip of 10IU oxytocin after delivery)
Study: 36218094
Drug: 1mg of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1mg of carboprost when the fetal head came out and then intramuscular injection of 20IU oxytocin
Study: 33983840
Drug: Oropharyngeal administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oropharyngeal administration of colostrum during mechanical ventilation
Study: 32668036
Drug: Endodontic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endodontic treatment with post-installation at the first visit (group 1)
Study: 32668036
Drug: Endodontic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endodontic treatment with post-installation at the second visit (group 2)
Study: 35850080
Drug: Olive Oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive Oil (OO) 3 g/day
Study: 35850080
Drug: Fish Oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish Oil (FO) 3 g/day
Study: 38341187
Drug: 17DD vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17DD vaccine
Study: 39406403
Drug: Bimekizumab 160
Normalized name: Bimekizumab 160 mg/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimekizumab 160 mg every 4 weeks
Study: 32854568
Drug: Roflumilast 250
Normalized name: ROFLUMILAST 250MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roflumilast 250 µg
Study: 37792369
Drug: Uncoated aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Uncoated aspirin
Study: 35977951
Drug: tinnitus retraining
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tinnitus retraining therapy
Study: 35977951
Drug: auditory discrimination
Approvals — FDA: no, EMA: no, PMDA: no
Description: auditory discrimination therapy
Study: 35977951
Drug: binaural beats
Approvals — FDA: no, EMA: no, PMDA: no
Description: binaural beats therapy
Study: 32358379
Drug: Chinese patent
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese patent medicine
Study: 39282906
Drug: Pembrolizumab-chemotherapy group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab-chemotherapy group
Study: 39282906
Drug: Placebo-chemotherapy group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-chemotherapy group
Study: 33251650
Drug: Topical sirolimus
Normalized name: sirolimus Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical sirolimus 0.2% cream plus Pulsed Dye Laser (PDL)
Study: 36892190
Drug: Denosumab (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab (60 mg)
Study: 32227216
Drug: Topiramate (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (maximum dosage of 300 mg for 13 weeks)
Study: 32452118
Drug: Isorhamnetin administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isorhamnetin administered orally for 21 consecutive days
Study: 32452118
Drug: Sildenafil administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil administered orally for 21 consecutive days
Study: 32945055
Drug: Intermittent theta
Normalized name: Coptis teeta root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent theta burst stimulation (iTBS), 1800 pulses/session, ten daily sessions
Study: 32307654
Drug: Immunotherapy (immune
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy (immune checkpoint inhibitors)
Study: 33917165
Drug: Green leafy
Normalized name: Green tea leaf
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green leafy vegetables (GLV) intervention, 1 cooked cup equivalent daily for 4 weeks
Study: 34475255
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment for acute ischemic stroke (AIS)
Study: 39423145
Drug: Deucravacitinib 6
Normalized name: deucravacitinib 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deucravacitinib 6 mg
Study: 36098968
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids, 1 g/d
Study: 35691183
Drug: Arginine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arginine (10 g)
Study: 34555839
Drug: IV cetirizine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV cetirizine 10 mg
Study: 34555839
Drug: IV diphenhydramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV diphenhydramine 50 mg
Study: 35854360
Drug: Oral fluoroquinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fluoroquinolone or trimethoprim-sulfamethoxazole
Study: 37858867
Drug: Intravenous therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous therapy
Study: 32334592
Drug: Twice-daily exenatide
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily exenatide
Study: 32334592
Drug: Insulin (aspartate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (aspartate 70/30)
Study: 33272368
Drug: Empagliflozin 10
Normalized name: empagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 10 mg once daily for 12 weeks
Study: 35348111
Drug: SB12 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB12 (300 mg dose via intravenous infusion)
Study: 35348111
Drug: Eculizumab (RP,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eculizumab (RP, 300 mg dose via intravenous infusion)
Study: 35040072
Drug: Neurodevelopmental Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurodevelopmental Therapy (NDT)
Study: 32948057
Drug: multi-DNA damage
Normalized name: Head & Shoulders Damage Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: multi-DNA damage response interference (mDDRi) as maintenance therapy
Study: 32948057
Drug: FOLFIRINOX treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRINOX treatment
Study: 36599736
Drug: HEV 239
Normalized name: Immunoglobulin G1-lambda2, anti-[Homo sapiens IL33 (interleukin 33, DVS27, NF-HEV, IL1F11)], monoclonal antibody; gamma1 heavy chain (1-456) [VH (Homo sapiens IGHV3-23*01 (93.9%) -(IGHD) -IGHJ4*01 (85.7%) L123>M (121)) CDR-IMGT [8.8.19] (26-33.51-58.97-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEV 239 vaccine
Study: 32004775
Drug: Therapeutic drug
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic drug monitoring (TDM) using a new HPLC-MS/MS method for quantifying dolutegravir (DTG), elvitegravir (ELV), rilpivirine (RPV), raltegravir (RAL), raltegravir‐Î²‐D‐glucuronide (RAL‐GLU), darunavir (DRV), and ritonavir (RTV) in human plasma.
Study: 33923171
Drug: 12 g
Normalized name: PEG-12 GLYCERYL LAURATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 g of mixed soluble and insoluble fiber for 8 weeks
Study: 32694162
Drug: Ferric Citrate
Normalized name: Ferric Citrate
DrugBank: Ferric sodium citrate (DB13771)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric Citrate (2 g three times a day with meals, n=30)
Study: 32694162
Drug: Ferrous Sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous Sulfate (325 mg three times a day, n=30)
Study: 35507383
Drug: 1 dose
Normalized name: Ribose 3 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of dexamethasone (0.6 mg/kg per dose, maximum of 16 mg)
Study: 35507383
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of dexamethasone (0.6 mg/kg per dose, maximum of 16 mg)
Study: 35507383
Drug: 1 dose
Normalized name: Ribose 3 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of dexamethasone
Study: 35507383
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of dexamethasone
Study: 34299697
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Therapy (CBT) as an adjunctive to treatment-as-usual (TAU)
Study: 32469095
Drug: Sponsor-provided drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sponsor-provided drugs
Study: 32736928
Drug: Intravesical mitomycin
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravesical mitomycin C (40 mg/40 ml) three times a week for 2 weeks
Study: 32736928
Drug: TURBT and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: TURBT and six weekly adjuvant instillations
Study: 36274158
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg progesterone daily for 4 days of abstinence
Study: 34061838
Drug: GMZ2 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GMZ2 vaccine adjuvanted with Cationic Adjuvant Formulation (CAF) 01
Study: 34061838
Drug: GMZ2 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GMZ2 vaccine adjuvanted with Alhydrogel
Study: 34061838
Drug: Control vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control vaccine (Rabies)
Study: 34167881
Drug: Combination supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination supplementation with vitamin B12 and folate
Study: 35122992
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of trans-resveratrol per day for four weeks
Study: 35122992
Drug: Placebo (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (500 mg wheat flour) for four weeks
Study: 33151315
Drug: TACE plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TACE plus ablative therapy (stereotactic body radiation therapy, microwave ablation, radiofrequency ablation)
Study: 33151315
Drug: TACE plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TACE plus ablative therapy
Study: 611775172
Drug: Intraperitoneal local
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal local anesthetic (20 mL 0.25% or 0.125% bupivacaine)
Study: 611775172
Drug: Control (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (20 mL 0.9% NaCl)
Study: 35724745
Drug: Itrīfal Shāhtra
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itrīfal Shāhtra (oral) and Marham Ḥina (topical)
Study: 35724745
Drug: PUVAsol (oral)
Normalized name: docusate sodium / sennosides, USP Oral Tablet [Purgasol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUVAsol (oral) and petrolatum (topical)
Study: 32416008
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment arms from CARE-HD
Study: 33571946
Drug: sc IFN
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sc IFN β‐1a (22 or 44 μg, three-times-weekly)
Study: 33687748
Drug: Insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin degludec 100 U/mL (IDeg‐100)
Study: 33378433
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) injections with CaCl2 activating solution
Study: 33378433
Drug: CaCl2 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: CaCl2 injection only (control)
Study: 33378433
Drug: Both PRP
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both PRP and CaCl2 injections
Study: 33629461
Drug: no treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: no treatment (negative control)
Study: 33833224
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (Lupron)‐induced ovarian suppression
Study: 35555329
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blocker (CCB) therapy (amlodipine)
Study: 35555329
Drug: CCB +
Normalized name: Calcium Channel Blocker Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCB + ACE inhibitor therapy
Study: 35555329
Drug: CCB +
Normalized name: Calcium Channel Blocker Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCB + ACE inhibitor + decreased salt intake
Study: 35555329
Drug: All antihypertensive
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All antihypertensive therapies
Study: 39500494
Drug: CytoSorb therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CytoSorb therapy
Study: 35896261
Drug: Oral Vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Vitamin B12 500 μg/day
Study: 35896261
Drug: Oral Vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Vitamin B12 1,500 μg/day
Study: 36456016
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of oral azithromycin